Synthesis of [123I]IBZM: A reliable procedure for routine clinical studies

Nuclear Medicine and Biology

Volumn 26, Issue 6, 1999, Pages 661-665

  Zea Ponce, Yolanda ^a,b   Laruelle, Marc ^a,b  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

^b Dept Neurosci New York Stt P   (United States)

Author keywords

123I IBZM; D2 receptor radiotracer; Iodobenzamide; SPECT

Indexed keywords

BENZAMIDE; DOPAMINE 2 RECEPTOR; IODINE 123; TRACER; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PERACETIC ACID; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ARTICLE; CONTROLLED STUDY; DRUG PURITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; METHODOLOGY; NONHUMAN; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS;

BENZAMIDES; DOPAMINE ANTAGONISTS; INDICATORS AND REAGENTS; IODINE RADIOISOTOPES; PERACETIC ACID; PYRROLIDINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032590035     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00031-1     Document Type: Article

References (14)

1. Angelberger P., Brucke Th., Podreka I., Zbiral E. Optimized preparation of I-123-IBZM and I-123-IBZP for clinical SPECT studies of D-2 and D-1 receptors. Proc. Int. Symp. Radiopharm. Chem. 1990;376-378.
2. 123I-IBZM. J. Lab. Comp. Radiopharm. 28:1990;1247-1256.
3. 123I]IBZM binding to the D2 receptor in non-human primates. Synapse. 10:1992;177-184.
4. Kung H.F., Alavi A., Chang W., Kung M.P., Keyes J.W. Jr, Velchik M.G., Billings J., Pan S., Noto R., Rausch A., Reilley J. In vivo SPECT imaging of CNS D-2 dopamine receptors Initial studies with iodine-123 IBZM in humans . J. Nucl. Med. 31:1990;573-579.
5. Kung H.F., Billings J.J., Guo Z., Mach R.H. Comparison of in vivo D-2 dopamine receptor binding of IBZM and NMSP in rat brain. Nucl. Med. Biol. 15:1988;203-208.
6. 123I]IBZM A potential CNS D-2 dopamine receptor imaging agent . Nucl. Med. Biol. 15:1988;195-201.
7. Kung H.F., Kasliwal R., Pan S., Kung M.P., Mach R.H., Guo Y.-Z. Dopamine D-2 receptor imaging radiopharmaceuticals Synthesis, radiolabeling and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl] benzamide . J. Med. Chem. 31:1988;1039-1043.
8. 123I]IBZM A potential CNS D-2 dopamine receptor imaging agent . J. Nucl. Med. 30:1989;88-92.
9. 123I]IBZM A potential dopamine D-2 receptor imaging agent . J. Lab. Comp. Radiopharm. 27:1989;691-700.
10. Kung M.P., Liu B.-L., Yang Y.-Y., Billings J.J., Kung H.F. A kit formulation for preparation of iodine-123-IBZM A new CNS D-2 dopamine receptor imaging agent . J. Nucl. Med. 32:1991;339-342.
11. Laruelle M., Abi-Dargham A., van Dick C.H., Rosenblat W., Zea-Ponce Y., Zoghbi S.S., Baldwin R.M., Charney D.S., Hoffer P.B., Kung H.F., Innis R.B. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 36:1995;1182-1190.
12. Laruelle M., iYer R.N., Al-Tikriti M.S., Zea-Ponce Y., Malison R., Zoghbi S.S., Baldwin R.M., Kung H.F., Charney D.S., Hoffer P.B., Innis R.B., Bradberry C.W. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse. 25:1997;1-14.
13. 2 receptors in human subjects with iodine-123-IBZM. J. Nucl. Med. 33:1992;1964-1971.
14. 123I]IBZM for SPECT imaging of human brain dopamine receptors Occupancy by the novel antipsychotic RWJ-37796 . J. Nucl. Med. 37:1996;11-15.